A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic

Drug repurposing is the only method capable of delivering treatments on the shortened time-scale required for patients afflicted with lung disease arising from SARS-CoV-2 infection. Mucin-1 (MUC1), a membrane-bound molecule expressed on the apical surfaces of most mucosal epithelial cells, is a bioc...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:bioRxiv
Autors principals: Alimova, Maria, Sidhom, Eriene-Heidi, Satyam, Abhigyan, Dvela-Levitt, Moran, Melanson, Michelle, Chamberlain, Brian T., Alper, Seth L., Santos, Jean, Gutierrez, Juan, Subramanian, Ayshwarya, Grinkevich, Elizabeth, Bricio, Estefania Reyes, Kim, Choah, Clark, Abbe, Watts, Andrew, Thompson, Rebecca, Marshall, Jamie, Pablo, Juan Lorenzo, Coraor, Juliana, Roignot, Julie, Vernon, Katherine A., Keller, Keith, Campbell, Alissa, Emani, Maheswarareddy, Racette, Matthew, Bazua-Valenti, Silvana, Padovano, Valeria, Weins, Astrid, McAdoo, Stephen P., Tam, Frederick W.K., Ronco, Lucienne, Wagner, Florence, Tsokos, George C., Shaw, Jillian L., Greka, Anna
Format: Artigo
Idioma:Inglês
Publicat: Cold Spring Harbor Laboratory 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7337390/
https://ncbi.nlm.nih.gov/pubmed/32637960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2020.06.30.180380
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars